Core Insights - The strategic collaboration between Lisata Therapeutics and GATC Health Corp aims to leverage GATC's AI-powered Multiomics Advanced Technology™ platform to optimize and derisk drug discovery and development processes, particularly for Lisata's investigational product, certepetide [1][2][5] Company Overview - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [2][8] - GATC Health Corp is a technology company that utilizes AI to transform drug discovery and development, with its MAT platform simulating billions of biological interactions to enhance drug development efficiency [10] Collaboration Details - The initial phase of the collaboration involves GATC's MAT AI analyzing certepetide to identify optimized development opportunities across various indications, including metastatic pancreatic ductal adenocarcinoma [3][4] - GATC's MAT AI will also explore potential drug combinations with certepetide for various indications beyond oncology [4] - The collaboration is expected to reduce traditional biopharmaceutical risks and enhance the probability of success for drug candidates, leading to more focused studies and shorter development timelines [5][6] Product Focus - Certepetide is designed to activate a novel uptake pathway for anti-cancer drugs, enhancing their ability to target and penetrate solid tumors effectively [9] - The drug has received multiple designations, including Fast Track and Orphan Drug Designation for pancreatic cancer, indicating its potential in treating serious conditions [9] Future Prospects - The collaboration is anticipated to lead to significant milestones over the next 1.5 years, with Lisata expecting its capital to support operations into the second quarter of 2026 [8]
Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development